AMT-562 in Patients With Selected Advanced Solid Tumors
This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: AMT-562
DLTs, Incidence of dose limiting toxicities, up to 24 month|AEs, Type, incidence and severity of Adverse Events, up to 24 month|SAEs, Type, incidence and severity Serious Adverse Events (SAEs), up to 24 month
Cmax, Maximum concentration (Cmax), up to 24 month|Tmax, time to peak drug concentration, up to 24 month|AUC, Area Under the Curve, up to 24 month|t1/2, terminal half-life of the ADC, total antibody and free payload, up to 24 month|ADAs, Specification and quantification of anti-drug antibodies, up to 24 month|ORR, Overall response rate assessed by the investigator according to RECIST version 1.1, up to 24 month|DCR, Disease control rate assessed by the investigator according to RECIST version 1.1, up to 24 month|PFS, Progression-free survival assessed by the investigator according to RECIST version 1.1, up to 24 month|TTR, Time to response assessed by the investigator according to RECIST version 1.1, up to 24 month|DOR, Duration of response assessed by the investigator according to RECIST version 1.1, up to 24 month
This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.